Edition:
United States

Fresenius SE & Co KGaA (FREG.DE)

FREG.DE on Xetra

69.14EUR
18 May 2018
Change (% chg)

-- (--)
Prev Close
€69.14
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,509,535
52-wk High
€80.07
52-wk Low
€58.96

Select another date:

Fri, May 18 2018

Photo

Fresenius CEO defends canceled Akorn deal

FRANKFURT/BERLIN Fresenius SE's chief executive has defended the company's decision to pull out of a planned $4.8 billion takeover of Akorn , saying it was the only option after uncovering data integrity breaches at the U.S drugmaker.

UPDATE 1-Fresenius CEO defends cancelled Akorn deal

* Expects legal proceedings to conclude in 2019 (Adds details on expenses, comment on provision, analyst)

BRIEF-Fresenius Costs Related To Akorn Total 60 Mln Euros So Far - CEO

* CEO SAYS COSTS RELATED TO AKORN TRANSACTION TOTAL 60 MILLION EUROS SO FAR

Fresenius CEO defends cancelled Akorn deal

FRANKFURT/BERLIN, May 18 Fresenius SE's chief executive has defended the company's decision to pull out of a planned $4.8 billion takeover of Akorn, saying it was the only option after uncovering data integrity breaches at the U.S drugmaker.

Fresenius sees Akorn lawsuit dragging on into 2019

BERLIN German healthcare group Fresenius SE said on Thursday its legal battle with Akorn over its canceled $4.7 billion takeover could drag on into 2019 as it posted a slight decline in quarterly profit hurt by a strong euro.

Fresenius Q1 net income slips 2 pct on strong euro

BERLIN, May 3 German healthcare group Fresenius SE posted a slight decline in quarterly profit on Thursday, hurt by a strong euro, and confirmed its full-year guidance.

Fresenius alleges 'blatant fraud' at U.S. drugmaker Akorn

WILMINGTON, Del./NEW YORK German healthcare group Fresenius alleged it uncovered "blatant fraud at the very top level" of U.S. generic drugmaker Akorn Inc after Fresenius agreed to acquire the company for $4.75 billion, according to a court filing made public late on Tuesday.

UPDATE 3-Fresenius alleges 'blatant fraud' at U.S. drugmaker Akorn

WILMINGTON, Del./NEW YORK, May 2 German healthcare group Fresenius alleged it uncovered "blatant fraud at the very top level" of U.S. generic drugmaker Akorn Inc after Fresenius agreed to acquire the company for $4.75 billion, according to a court filing made public late on Tuesday.

Fresenius alleges "blatant fraud" at abandoned target Akorn

WILMINGTON, Del., May 2 German healthcare group Fresenius alleged it uncovered "blatant fraud at the very top level" of U.S. generic drugmaker Akorn Inc after Fresenius agreed to acquire the company for $4.75 billion, according to a filing in Delaware's Court of Chancery.

BRIEF-Fresenius says believes that Akorn lawsuit is without foundation

* AKORN, INC. SUES FRESENIUS FOR CONSUMMATION OF MERGER AGREEMENT AFTER ITS TERMINATION BY FRESENIUS

Select another date: